Pharmacology MCQ PDF - Volga State Medical University 2006

State Educational Institution of the Higher Professional Education VOLGOGRAD STATE MEDICAL UNIVERSITY of Federal Agency for Public Health and Social Development Pharmacology Department MULTIPLE-CHOICE TESTS IN PHARMACOLOGY VOLOGOGRAD 2006 2 ГОСУДАРСТВЕННОЕ ОБРАЗОВАТЕЛЬНОЕ УЧРЕЖДЕНИЕ ВЫСШЕГО ПРОФЕССИОНАЛЬНОГО ОБРАЗОВАНИЯ ВОЛГОГРАДСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ КАФЕДРА ФАРМАКОЛОГИИ В.А. КОСОЛАПОВ, М.В. ЧЕРНИКОВ, О.Ю. ГРЕЧКО, И.Н. ИЕЖИЦА, А.Ф. КУЧЕРЯВЕНКО ТЕСТОВЫЕ ВОПРОСЫ ПО ФАРМАКОЛОГИИ УЧЕБНОЕ ПОСОБИЕ Под редакцией Член-корреспондента РАМН, заслуженного деятеля науки РФ, доктора медицинских наук, профессора А.А. Спасова и кандидата филологических наук В.В. Жура Рекомендовано к печати УЧЕБНО-МЕТОДИЧЕСКИМ ОБЪЕДИНЕНИЕМ ПО МЕДИЦИНСКОМУ И ФАРМАЦЕВТИЧЕСКОМУ ОБРАЗОВАНИЮ ВУЗОВ РОССИИ В КАЧЕСТВЕ УЧЕБНОГО ПОСОБИЯ ДЛЯ ИНОСТРАННЫХ СТУДЕНТОВ МЕДИЦИНСКИХ ВУЗОВ, ОБУЧАЮЩИХСЯ НА АНГЛИЙСКОМ ЯЗЫКЕ ОТ ________ УМО-_____ Волгоград 2006 3 УДК 615(07) ТЕСТОВЫЕ ВОПРОСЫ ПО ФАРМАКОЛОГИИ: Учебное пособие / В.А. КОСОЛАПОВ, М.В. ЧЕРНИКОВ, О.Ю. ГРЕЧКО, И.Н. ИЕЖИЦА, А.Ф. КУЧЕРЯВЕНКО / Под ред. АА. Спасова, В.В Жура. – Волгоград, 2005. –___с. РЕЦЕНЗЕНТЫ: Зав. кафедрой фармакологии и биофармации ФУВ ВолгМУ, д.м.н., профессор И.Н. Тюренков Зав. кафедрой фармакологии фармацевтического факультета Московской медицинской академии им. Сеченова, профессор, д.м.н. Р.Н. Аляутдин Зав. кафедрой фармакологии Саратовского медицинского университета, д.м.н., профессор А.А. Свистунов © Волгоградский государственный медицинский университет 2006 4 Contents Chapter Pages (1) GENERAL PRINCIPLES OF PHARMACOLOGY............................................................................................... 5 PART I PHARMACOKINETICS........................................................................................................................................ 5 PART II PHARMACODYNAMICS.................................................................................................................................... 8 (2) AGENTS, CONTROLLING THE FUNCTIONS OF THE PERIPHERAL NERVOUS SYSTEM................. 12 PART I LOCAL ANESTHETICS.............................................................................................................................................. 12 PART II CHOLINOMIMETIC DRUGS...................................................................................................................................... 16 PART III CHOLINORECEPTOR BLOCKING DRUGS................................................................................................................. 19 PART IV ADRENORECEPTOR ACTIVATING DRUGS............................................................................................................... 24 PART V ADRENORECEPTOR ANTAGONIST DRUGS............................................................................................................... 29 (3) AGENTS, CONTROLLING THE FUNCTIONS OF THE CENTRAL NERVOUS SYSTEM........................ 34 PART I HYPNOTIC DRUGS................................................................................................................................................... 34 PART II ANTISEIZURE DRUGS............................................................................................................................................. 38 PART III ANTIPARKINSONIAN AGENTS................................................................................................................................ 41 PART IV ETHYL ALCOHOL.................................................................................................................................................. 44 PART V NARCOTIC ANALGESICS......................................................................................................................................... 46 PART VI NON-NARCOTIC ANALGESICS............................................................................................................................... 49 PART VII ANTIPSYCHOTIC AGENTS.................................................................................................................................... 51 PART VIII ANTIDEPRESSANT AGENTS................................................................................................................................ 54 PART IX ANXIOLYTIC AGENTS........................................................................................................................................... 57 PART X CNS STIMULANTS................................................................................................................................................. 60 PART XI DRUGS OF ABUSE................................................................................................................................................. 63 PART XII GENERAL ANESTHETICS...................................................................................................................................... 65 (4) ORGANOTROPIC AGENTS.................................................................................................................................. 68 PART I DRUGS ACTING ON RESPIRATORY SYSTEM.............................................................................................................. 68 PART II DRUGS USED IN GASTROINTESTINAL DISEASES...................................................................................................... 70 PART III DRUGS ACTING ON HEMATOPOIETIC SYSTEM........................................................................................................ 73 PART IV DRUGS USED IN DISORDERS OF COAGULATION..................................................................................................... 74 PART V DRUGS USED FOR TREATMENT OF HEART FAILURE................................................................................................ 76 PART VI ANTIARRHYTHMIC AGENTS.................................................................................................................................. 78 PART VII DRUGS FOR ANGINA PECTORIS TREATMENT....................................................................................................... 80 PART VIII ANTIHYPERTENSIVE DRUGS............................................................................................................................... 83 PART IX HYPERTENSIVE (ANTI-HYPOTENSIVE) DRUGS. DRUGS INFLUENCING CEREBRAL BLOOD FLOW. ANTI-MIGRAINE AGENTS................................................................................................................................................................................ 85 (5) METABOLIC PROFILE DRUGS.......................................................................................................................... 88 PART I HYPOTHALAMIC & PITUITARY HORMONES, THYROID & ANTITHYROID DRUGS..................................................... 88 PART II PANCREATIC HORMONES & ANTIDIABETIC DRUGS............................................................................................... 91 PART III THE GONADAL HORMONES & INHIBITORS........................................................................................................... 93 PART IV GLUCOCORTICOID, STEROIDAL & NONSTEROIDAL ANTI-INFLAMMATORY DRUGS.............................................. 95 PART V IMMUNOTROPIC & ANTIALLERGIC AGENTS.......................................................................................................... 98 PART VI VITAMINS, VITAMIN-LIKE COMPOUNDS, ANTIVITAMINS, ENZYMES & ANTIENZYMES...................................... 104 PART VII ANTIHYPERLIPIDEMIC DRUGS & DRUGS USED IN THE TREATMENT OF GOUT.................................................. 110 PART VIII AGENTS THAT AFFECT BONE MINERAL HOMEOSTASIS.................................................................................. 114 PART IX MINERALOCORTICOID, MINERALOCORTICOID ANTAGONISTS, DIURETICS, PLASMA EXPANDERS...................... 120 (6) CHEMOTHERAPEUTIC DRUGS....................................................................................................................... 124 PART I ANTIBIOTICS.................................................................................................................................................... 124 PART II SYNTHETIC ANTIBACTERIAL DRUGS....................................................................................................... 129 PART III ANTIPROTOZOAL AND ANTHELMINTIC DRUGS................................................................................... 132 PART IV ANTIVIRAL AGENTS. AGENTS FOR CHEMOTHERAPY OF CANCER.................................................. 135 5 (1) GENERAL PRINCIPLES OF PHARMACOLOGY PART I PHARMACOKINETICS 001. Pharmacokinetics is: a) The study of biological and therapeutic effects of drugs b) The study of absorption, distribution, metabolism and excretion of drugs c) The study of mechanisms of drug action d) The study of methods of new drug development 002. What does “pharmacokinetics” include? a) Complications of drug therapy b) Drug biotransformation in the organism c) Influence of drugs on metabolism processes d) Influence of drugs on genes 002. What does “pharmacokinetics” include? a) Pharmacological effects of drugs b) Unwanted effects of drugs c) Chemical structure of a medicinal agent d) Distribution of drugs in the organism 003. What does “pharmacokinetics” include? a) Localization of drug action b) Mechanisms of drug action c) Excretion of substances d) Interaction of substances 004. The main mechanism of most drugs absorption in GI tract is: a) Active transport (carrier-mediated diffusion) b) Filtration (aqueous diffusion) c) Endocytosis and exocytosis d) Passive diffusion (lipid diffusion) 005. What kind of substances can’t permeate membranes by passive diffusion? a) Lipid-soluble b) Non-ionized substances c) Hydrophobic substances d) Hydrophilic substances 006. A hydrophilic medicinal agent has the following property: a) Low ability to penetrate through the cell membrane lipids b) Penetrate through membranes by means of endocytosis c) Easy permeation through the blood-brain barrier d) High reabsorption in renal tubules 007. What is implied by «active transport»? a) Transport of drugs trough a membrane by means of diffusion b) Transport without energy consumption c) Engulf of drug by a cell membrane with a new vesicle formation d) Transport against concentration gradient 008. What does the term “bioavailability” mean? a) Plasma protein binding degree of substance b) Permeability through the brain-blood barrier c) Fraction of an uncharged drug reaching the systemic circulation following any route administration d) Amount of a substance in urine relative to the initial doze 009. The reasons determing bioavailability are: a) Rheological parameters of blood b) Amount of a substance obtained orally and quantity of intakes c) Extent of absorption and hepatic first-pass effect d) Glomerular filtration rate 010. Pick out the appropriate alimentary route of administration when passage of drugs through liver is minimized: a) Oral b) Transdermal c) Rectal d) Intraduodenal 011. Which route of drug administration is most likely to lead to the first-pass effect? a) Sublingual 6 b) Oral c) Intravenous d) Intramuscular 012. What is characteristic of the oral route? a) Fast onset of effect b) Absorption depends on GI tract secretion and motor function c) A drug reaches the blood passing the liver d) The sterilization of medicinal forms is obligatory 013. Tick the feature of the sublingual route: a) Pretty fast absorption b) A drug is exposed to gastric secretion c) A drug is exposed more prominent liver metabolism d) A drug can be administrated in a variety of doses 014. Pick out the parenteral route of medicinal agent administration: a) Rectal b) Oral c) Sublingual d) Inhalation 015. Parenteral administration: a) Cannot be used with unconsciousness patients b) Generally results in a less accurate dosage than oral administration c) Usually produces a more rapid response than oral administration d) Is too slow for emergency use 016. What is characteristic of the intramuscular route of drug administration? a) Only water solutions can be injected b) Oily solutions can be injected c) Opportunity of hypertonic solution injections d) The action develops slower, than at oral administration 017. Intravenous injections are more suitable for oily solutions: a) True b) False 018. Correct statements listing characteristics of a particular route of drug administration include all of the following EXCEPT: a) Intravenous administration provides a rapid response b) Intramuscular administration requires a sterile technique c) Inhalation provides slow access to the general circulation d) Subcutaneous administration may cause local irritation 019. Most of drugs are distributed homogeneously. a) True b) False 020. Biological barriers include all except: a) Renal tubules b) Cell membranes c) Capillary walls d) Placenta 021. What is the reason of complicated penetration of some drugs through brain-blood barrier? a) High lipid solubility of a drug b) Meningitis c) Absence of pores in the brain capillary endothelium d) High endocytosis degree in a brain capillary 022. The volume of distribution (Vd) relates: a) Single to a daily dose of an administrated drug b) An administrated dose to a body weight c) An uncharged drug reaching the systemic circulation d) The amount of a drug in the body to the concentration of a drug in plasma 023. For the calculation of the volume of distribution (Vd) one must take into account: a) Concentration of a substance in plasma b) Concentration of substance in urine c) Therapeutical width of drug action d) A daily dose of drug 024. A small amount of the volume of distribution is common for lipophylic substances easy penetrating through barriers and widely distributing in plasma, interstitial and cell fluids: 7 a) True b) False 025. The term “biotransformation” includes the following: a) Accumulation of substances in a fat tissue b) Binding of substances with plasma proteins c) Accumulation of substances in a tissue d) Process of physicochemical and biochemical alteration of a drug in the body 026. Biotransformation of the drugs is to render them: a) Less ionized b) More pharmacologically active c) More lipid soluble d) Less lipid soluble 027. Tick the drug type for which microsomal oxidation is the most prominent: a) Lipid soluble b) Water soluble c) Low molecular weight d) High molecular weight 028. Pick out the right statement: a) Microsomal oxidation always results in inactivation of a compound b) Microsomal oxidation results in a decrease of compound toxicity c) Microsomal oxidation results in an increase of ionization and water solubility of a drug d) Microsomal oxidation results in an increase of lipid solubility of a drug thus its excretion from the organism is facilitated 029. Stimulation of liver microsomal enzymes can: a) Require the dose increase of some drugs b) Require the dose decrease of some drugs c) Prolong the duration of the action of a drug d) Intensify the unwanted reaction of a drug 030. Metabolic transformation (phase 1) is: a) Acetylation and methylation of substances b) Transformation of substances due to oxidation, reduction or hydrolysis c) Glucuronide formation d) Binding to plasma proteins 031. Biotransformation of a medicinal substance results in: a) Faster urinary excretion b) Slower urinary excretion c) Easier distribution in organism d) Higher binding to membranes 032. Conjugation is: a) Process of drug reduction by special enzymes b) Process of drug oxidation by special oxidases c) Coupling of a drug with an endogenous substrate d) Solubilization in lipids 033. Which of the following processes proceeds in the second phase of biotransformation? a) Acetylation b) Reduction c) Oxidation d) Hydrolysis 034. Conjugation of a drug includes the following EXCEPT: a) Glucoronidation b) Sulfate formation c) Hydrolysis d) Methylation 035. Metabolic transformation and conjugation usually results in an increase of a substance biological activity: a) True b) False 036. In case of liver disorders accompanied by a decline in microsomal enzyme activity the duration of action of some drugs is: a) Decreased b) Enlarged c) Remained unchanged d) Changed insignificantly 8 037. Half life (t ½) is the time required to: a) Change the amount of a drug in plasma by half during elimination b) Metabolize a half of an introduced drug into the active metabolite c) Absorb a half of an introduced drug d) Bind a half of an introduced drug to plasma proteins 038. Half life (t ½) doesn’t depend on: a) Biotransformation b) Time of drug absorption c) Concentration of a drug in plasma d) Rate of drug elimination 039. Elimination is expressed as follows: a) Rate of renal tubular reabsorption b) Clearance speed of some volume of blood from substance c) Time required to decrease the amount of drug in plasma by one-half d) Clearance of an organism from a xenobiotic 040. Elimination rate constant (Kelim) is defined by the following parameter: a) Rate of absorption b) Maximal concentration of a substance in plasma c) Highest single dose d) Half life (t ½) 041. The most rapid eliminated drugs are those with high glomerular filtration rate and actively secreted but aren’t passively reabsorbed: a) True b) False 042. Systemic clearance (CLs) is related with: a) Only the concentration of substances in plasma b) Only the elimination rate constant c) Volume of distribution, half life and elimination rate constant d) Bioavailability and half life PART II PHARMACODYNAMICS 001. Pharmacodynamics involves the study of following EXCEPT: a) Biological and therapeutic effects of drugs b) Absorption and distribution of drugs c) Mechanisms of drug action d) Drug interactions 002. Pharmacodynamics involves the study of following? a) Mechanisms of drug action b) Biotransformation of drugs in the organism c) Distribution of drugs in the organism d) Excretion of drug from the organism 003. Pharmacodynamics involves the following? a) Information about main mechanisms of drug absorption b) Information about unwanted effects c) Information about biological barriers d) Information about excretion of a drug from the organism 004. Pick out the answer which is the most appropriate to the term “receptor” a) All types of ion channels modulated by a drug b) Enzymes of oxidizing-reducing reactions activated by a drug c) Active macromolecular components of a cell or an organism which a drug molecule has to combine with in order to elicit its specific effect d) Carriers activated by a drug 005. What does “affinity” mean? a) A measure of how tightly a drug binds to plasma proteins b) A measure of how tightly a drug binds to a receptor c) A measure of inhibiting potency of a drug d) A measure of bioavailability of a drug 006. Target proteins which a drug molecule binds are: a) Only receptors b) Only ion channels c) Only carriers 9 d) All of the above 007. An agonist is a substance that: a) Interacts with the receptor without producing any effect b) Interacts with the receptor and initiates changes in cell function, producing various effects c) Increases concentration of another substance to produce effect d) Interacts with plasma proteins and doesn’t produce any effect 008. If an agonist can produce maximal effects and has high efficacy it’s called: a) Partial agonist b) Antagonist c) Agonist-antagonist d) Full agonist 009. If an agonist can produce submaximal effects and has moderate efficacy it’s called: a) Partial agonist b) Antagonist c) Agonist-antagonist d) Full agonist 010. An antagonist is a substance that: a) Binds to the receptors and initiates changes in cell function, producing maximal effect b) Binds to the receptors and initiates changes in cell function, producing submaximal effect c) Interacts with plasma proteins and doesn’t produce any effect d) Binds to the receptors without directly altering their functions 011. A competitive antagonist is a substance that: a) Interacts with receptors and produces submaximal effect b) Binds to the same receptor site and progressively inhibits the agonist response c) Binds to the nonspecific sites of tissue d) Binds to one receptor subtype as an agonist and to another as an antagonist 012. The substance binding to one receptor subtype as an agonist and to another as an antagonist is called: a) Competitive antagonist b) Irreversible antagonist c) Agonist-antagonist d) Partial agonist 013. Irreversible interaction of an antagonist with a receptor is due to: a) Ionic bonds b) Hydrogen bonds c) Covalent bonds d) All of the above 014. Mechanisms of transmembrane signaling are the following EXCEPT: a) Transmembrane receptors that bind and stimulate a protein tyrosine kinase b) Gene replacement by the introduction of a therapeutic gene to correct a genetic effect c) Ligand-gated ion channels that can be induced to open or close by binding a ligand d) Transmembrane receptor protein that stimulates a GTP-binding signal transducer protein (G-protein) which in turn generates an intracellular second messenger 015. Tick the second messenger of G-protein-coupled (metabotropic) receptor: a) Adenylyl cyclase b) Sodium ions c) Phospholipase C d) cAMP 016. Tick the substance which changes the activity of an effector element but doesn’t belong to second messengers: a) cAMP b) cGMP c) G–protein d) Calcium ions 017. The increase of second messengers’ (cAMP, cGMP, Ca2+ etc.) concentration leads to: a) Inhibition of intracellular protein kinases and protein phosphorylation b) Proteinkinases activation and protein phosphorylation c) Blocking of interaction between a receptor and an effector d) Antagonism with endogenous ligands 018. Tick the substances whose mechanisms are based on interaction with ion channels a) Sodium channel blockers b) Calcium channel blockers c) Potassium channels activators 10 d) All of the above 019. All of the following statements about efficacy and potency are true EXCEPT: a) Efficacy is usually a more important clinical consideration than potency b) Efficacy is the maximum effect of a drug c) Potency is a comparative measure, refers to the different doses of two drugs that are needed to produce the same effect d) The ED50 is a measure of drug’s efficacy 020. Give the definition for a therapeutical dose: a) The amount of a substance to produce the minimal biological effect b) The amount of a substance to produce effects hazardous for an organism c) The amount of a substance to produce the required effect in most patients d) The amount of a substance to accelerate an increase of concentration of medicine in an organism 021. Pick out the correct definition of a toxic dose: a) The amount of substance to produce the minimal biological effect b) The amount of substance to produce effects hazardous for an organism c) The amount of substance to produce the necessary effect in most of patients d) The amount of substance to fast creation of high concentration of medicine in an organism 022. Which effect may lead to toxic reactions when a drug is taken continuously or repeatedly? a) Refractoriness b) Cumulative effect c) Tolerance d) Tachyphylaxis 023. What term is used to describe a more gradual decrease in responsiveness to a drug, taking days or weeks to develop? a) Refractoriness b) Cumulative effect c) Tolerance d) Tachyphylaxis 024. What term is used to describe a decrease in responsiveness to a drug which develops in a few minutes? a) Refractoriness b) Cumulative effect c) Tolerance d) Tachyphylaxis 025. Tachyphylaxis is: a) A drug interaction between two similar types of drugs b) Very rapidly developing tolerance c) A decrease in responsiveness to a drug, taking days or weeks to develop d) None of the above 026. Drug resistance is a term used to describe the loss of effectiveness of antimicrobial or antitumour drugs. This consideration is: a) True b) False 027. Tolerance and drug resistance can be a consequence of: a) Drug dependence b) Increased metabolic degradation c) Depressed renal drug excretion d) Activation of a drug after hepatic first-pass 028. Tolerance and drug resistance can be a consequence of: a) Change in receptors, loss of them or exhaustion of mediators b) Increased receptor sensitivity c) Decreased metabolic degradation d) Decreased renal tubular secretion 029. Tolerance develops because of: a) Diminished absorption b) Rapid excretion of a drug c) Both of the above d) None of the above 030. Dependence is often associated with tolerance to a drug, a physical abstinence syndrome, and psychological dependence (craving). This consideration is: a) True b) False 11 031. The situation when failure to continue administering the drug results in serious psychological and somatic disturbances is called? a) Tachyphylaxis b) Sensibilization c) Abstinence syndrome d) Idiosyncrasy 032. What is the type of drug-to-drug interaction which is connected with processes of absorption, biotransformation, distribution and excretion? a) Pharmacodynamic interaction b) Physical and chemical interaction c) Pharmaceutical interaction d) Pharmacokinetic interaction 033. What is the type of drug-to-drug interaction which is the result of interaction at receptor, cell, enzyme or organ level? a) Pharmacodynamic interaction b) Physical and chemical interaction c) Pharmaceutical interaction d) Pharmacokinetic interaction 034. What phenomenon can occur in case of using a combination of drugs? a) Tolerance b) Tachyphylaxis c) Accumulation d) Synergism 035. If two drugs with the same effect, taken together, produce an effect that is equal in magnitude to the sum of the effects of the drugs given individually, it is called as: a) Antagonism b) Potentiation c) Additive effect d) None of the above 036. What does the term “potentiation” mean? a) Cumulative ability of a drug b) Hypersensitivity to a drug c) Fast tolerance developing d) Intensive increase of drug effects due to their combination 037. The types of antagonism are: a) Summarized b) Potentiated c) Additive d) Competitive 038. The term “chemical antagonism” means that: a) two drugs combine with one another to form an inactive compound b) two drugs combine with one another to form a more active compound c) two drugs combine with one another to form a more water soluble compound d) two drugs combine with one another to form a more fat soluble compound 039. A teratogenic action is: a) Toxic action on the liver b) Negative action on the fetus causing fetal malformation c) Toxic action on blood system d) Toxic action on kidneys 040. Characteristic unwanted reaction which isn’t related to a dose or to a pharmacodynamic property of a drug is called: a) Idiosyncrasy b) Hypersensitivity c) Tolerance d) Teratogenic action 041. Idiosyncratic reaction of a drug is: a) A type of hypersensitivity reaction b) A type of drug antagonism c) Unpredictable, inherent, qualitatively abnormal reaction to a drug d) Quantitatively exaggerated response 042. Therapeutic index (TI) is: a) A ratio used to evaluate the safety and usefulness of a drug for indication b) A ratio used to evaluate the effectiveness of a drug 12 c) A ratio used to evaluate the bioavailability of a drug d) A ratio used to evaluate the elimination of a drug (2) AGENTS, CONTROLLING THE FUNCTIONS OF THE PERIPHERAL NERVOUS SYSTEM PART I Local anesthetics 001. Local anesthetics produce: a) Analgesia, amnesia, loss of consciousness b) Blocking pain sensation without loss of consciousness c) Alleviation of anxiety and pain with an altered level of consciousness d) A stupor or somnolent state 002. A good local anesthetic agent shouldn’t cause: a) Local irritation and tissue damage b) Systemic toxicity c) Fast onset and long duration of action d) Vasodilatation 003. Most local anesthetic agents consist of: a) Lipophylic group (frequently an aromatic ring) b) Intermediate chain (commonly including an ester or amide) c) Amino group d) All of the above 004. Which one of the following groups is responsible for the duration of the local anesthetic action? a) Intermediate chain b) Lipophylic group c) Ionizable group d) All of the above 005. Indicate the local anesthetic agent, which has a shorter duration of action: a) Lidocaine b) Procaine c) Bupivacaine d) Ropivacaine 006. Which one of the following groups is responsible for the potency and the toxicity of local anesthetics? a) Ionizable group b) Intermediate chain c) Lipophylic group d) All of the above 007. Indicate the drug, which has greater potency of the local anesthetic action: a) Lidocaine b) Bupivacaine c) Procaine d) Mepivacaine 008. Ionizable group is responsible for: a) The potency and the toxicity b) The duration of action c) The ability to diffuse to the site of action d) All of the above 009. Which one of the following local anesthetics is an ester of benzoic acid? a) Lidocaine b) Procaine c) Ropivacaine d) Cocaine 010. Indicate the local anesthetic, which is an ester of paraaminobenzoic acid: a) Mepivacaine b) Cocaine c) Procaine d) Lidocaine 011. Which of the following local anesthetics is an acetanilide derivative? a) Tetracaine b) Lidocaine c) Cocaine d) Procaine 13 012. Indicate the local anesthetic, which is a toluidine derivative: a) Lidocaine b) Bupivacaine c) Prilocaine d) Procaine 013. Which of the following local anesthetics is a thiophene derivative? a) Procaine b) Ultracaine c) Lidocaine d) Mepivacaine 014. Local anesthetics are: a) Weak bases b) Weak acids c) Salts d) None of the above 015. For therapeutic application local anesthetics are usually made available as salts for the reasons of: a) Less toxicity and higher potency b) Higher stability and greater lipid solubility c) Less local tissue damage and more potency d) More stability and greater water solubility 016. Which of the following statements is not correct for local anesthetics? a) In a tissue they exist either as an uncharged base or as a cation b) A charged cationic form penetrates biologic membranes more readily than an uncharged form c) Local anesthetics are much less effective in inflamed tissues d) Low ph in inflamed tissues decreases the dissociation of nonionized molecules 017. Which one of the following statements about the metabolism of local anesthetics is incorrect? a) Metabolism of local anesthetics occurs at the site of administration b) Metabolism occurs in the plasma or liver but not at the site of administration c) Ester group of anesthetics like procaine, are metabolized systemically by pseudocholinesterase d) Amides such as lidocaine, are metabolized in the liver by microsomal mixed function oxidases 018. Indicate the anesthetic agent of choice in patient with a liver disease: a) Lidocaine b) Bupivacaine c) Procaine d) Etidocaine 019. Which of the following local anesthetics is preferable in patient with pseudocholinesterase deficiency? a) Procaine b) Ropivacaine c) Tetracaine d) Benzocaine 020. The primary mechanism of action of local anesthetics is: a) Activation of ligand-gated potassium channels b) Blockade of voltage-gated sodium channels c) Stimulation of voltage-gated N-type calcium channels d) Blockade the GABA-gated chloride channels 021. Which of the following local anesthetics is more water-soluble? a) Tetracaine b) Etidocaine c) Procaine d) Bupivacaine 022. Indicate the local anesthetic, which is more lipid-soluble: a) Bupivacaine b) Lidocaine c) Mepivacaine d) Procaine 023. The more lipophylic drugs: a) Are more potent b) Have longer duration of action c) Bind more extensively to proteins d) All of the above 024. Which of the following fibers is the first to be blocked? 14 a) Type A alpha fibers b) B and C fibers c) Type A beta fibers d) Type A gamma fibers 025. Indicate the function, which the last to be blocked: a) Pain, temperature b) Muscle spindles c) Motor function d) Touch, pressure 026. Which of the following fibers participates in high-frequency pain transmission? a) Type A delta and C fibers b) Type A alpha fibers c) Type B fibers d) Type A beta fibers 027. Which of the following local anesthetics is an useful antiarrhythmic agent? a) Cocaine b) Lidocaine c) Bupivacaine d) Ropivacaine 028. Indicate the route of local anesthetic administration, which is associated with instillation within epidural or subarachnoid spaces: a) Topical anesthesia b) Infiltrative anesthesia c) Regional anesthesia d) Spinal anesthesia 029. The choice of a local anesthetic for specific procedures is usually based on: a) The duration of action b) Water solubility c) Capability of rapid penetration through the skin or mucosa with limited tendency to diffuse away from the site of application d) All of the above 030. Which of the following local anesthetics is a short-acting drug? a) Procaine b) Tetracaine c) Bupivacaine d) Ropivacaine 031. Indicate the local anesthetic, which is a long-acting agent: a) Lidocaine b) Bupivacaine c) Procaine d) Mepivacaine 032. The anesthetic effect of the agents of short and intermediate duration of action can not be prolonged by adding: a) Epinephrine b) Norepinephrine c) Dopamine d) Phenylephrine 033. A vasoconstrictor does not: a) Retard the removal of drug from the injection site b) Hence the chance of toxicity c) Decrease the blood level d) Reduce a local anesthetic uptake by the nerve 034. Vasoconstrictors are less effective in prolonging anesthetic properties of: a) Procaine b) Bupivacaine c) Lidocaine d) Mepivacaine 035. Which of the following local anesthetics is only used for surface or topical anesthesia? a) Cocaine b) Tetracaine c) Procaine d) Bupivacaine 15 036. Indicate the local anesthetic, which is mainly used for regional nerve block anesthesia: a) Dibucaine b) Bupivacaine c) Tetracaine d) Cocaine 037. Which of the following local anesthetics is used for infiltrative and regional anesthesia? a) Procaine b) Lidocaine c) Mepivacaine d) All of the above 038. Indicate the local anesthetic, which is used for spinal anesthesia: a) Tetracaine b) Cocaine c) Dibucaine d) Bupivacaine 039. Which of the following local anesthetics is called a universal anesthetic? a) Procaine b) Ropivacaine c) Lidocaine d) Bupivacaine 040. Most serious toxic reaction to local anesthetics is: a) Seizures b) Cardiovascular collapse c) Respiratory failure d) All of the above 041. Correct statements concerning cocaine include all of the following EXCEPT: a) Cocaine is often used for nose and throat procedures b) Limited use because of abuse potential c) Myocardial depression and peripheral vasodilatation d) Causes sympathetically mediated tachycardia and vasoconstriction 042. Which of the following local anesthetics is more cardiotoxic? a) Procaine b) Bupivacaine c) Lidocaine d) Mepivacaine 043. Most local anesthetics can cause: a) Depression of abnormal cardiac pacemaker activity, excitability, conduction b) Depression of the strength of cardiac contraction c) Cardiovascular collapse d) All of the above 044. Which one of the following local anesthetics causes methemoglobinemia? a) Prilocaine b) Procaine c) Lidocaine d) Ropivacaine 045. Procaine has all of the following properties EXCEPT: a) It has ester linkage b) Its metabolic product can inhibit the action of sulfonamides c) It readily penetrates the skin and mucosa d) It is relatively short-acting 046. Correct statements concerning lidocaine include all of the following EXCEPT: a) It is an universal anesthetic b) It has esteratic linkage c) It widely used as an antiarrhythmic agent d) It is metabolized in liver 047. Which of the following local anesthetics is more likely to cause allergic reactions? a) Lidocaine b) Bupivacaine c) Procaine d) Ropivacaine 048. Tetracaine has all of the following properties EXCEPT: 16 a) Slow onset b) Low potency c) Long duration d) High toxicity 049. Correct statements concerning bupivacaine include all of the following EXCEPT: a) It has low cardiotoxicity b) It has amide linkage c) It is a long-acting drug d) An intravenous injection can lead to seizures PART II Cholinomimetic drugs 001. Acetylcholine is not a specific neurotransmitter at: a) Sympathetic ganglia b) Sympathetic postganglionic nerve endings c) Parasympathetic ganglia d) Parasympathetic postganglionic nerve endings 002. Muscarinic receptors are located in: a) Autonomic ganglia b) Skeletal muscle neuromuscular junctions c) Autonomic effector cells d) Sensory carotid sinus baroreceptor zone 003. Indicate the location of M2 cholinoreceptor type: a) Heart b) Glands c) Smooth muscle d) Endothelium 004. The symptoms of mushroom poisoning include all of the following EXCEPT: a) Salivation, lacrimation, nausea, vomiting b) Dryness of mouth, hyperpyrexia, hallucination c) Headache, abdominal colic d) Bradycardia, hypotension and shock 005. Which of the following cholinomimetics activates both muscarinic and nicotinic receptors? a) Lobeline b) Pilocarpine c) Nicotine d) Bethanechol 006. Indicate a cholinomimetic agent, which is related to direct-acting drugs: a) Edrophonium b) Physostigmine c) Carbachol d) Isoflurophate 007. Characteristics of carbachol include all of the following EXCEPT: a) It decreases intraocular pressure b) It causes mydriasis c) It exerts both nicotinic and muscarinic effects d) It is resistant to acethylcholiesterase 008. Acetylcholine is not used in clinical practice because: a) It is very toxic b) The doses required are very high c) It is very rapidly hydrolyzed d) It is very costly 009. Parasympathomimetic drugs cause: a) Bronchodilation b) Mydriasis c) Bradycardia d) Constipation 010. Which of the following direct-acting cholinomimetics is mainly muscarinic in action? a) Bethanechol b) Carbachol c) Acetylcholine d) None of the above 17 011. Which of the following direct-acting cholinomimetics has the shortest duration of action? a) Acetylcholine b) Methacholine c) Carbachol d) Bethanechol 012. Bethanechol has all of the following properties EXCEPT: a) It is extremely resistant to hydrolysis b) Purely muscarinic in its action c) It is used for abdominal urinary bladder distention d) It exerts both nicotinic and muscarinic effects 013. A M-cholinimimetic agent is: a) Carbachol b) Pilocarpine c) Acetylcholine d) Bethanechol 014. Characteristics of pilocarpine include all of the following EXCEPT: a) It is a tertiary amine alkaloid b) It causes miosis and a decrease in intraocular pressure c) Causes a decrease in secretory and motor activity of gut d) It is useful in the treatment of glaucoma 015. Which of the following cholinomimetics is a plant derivative with lower potency than nicotine but with a similar spectrum of action? a) Lobeline b) Pilocarpine c) Carbochol d) Acetylcholine 016. Which of the following cholinomimetics is indirect-acting? a) Lobeline b) Edrophonium c) Pilocarpine d) Carbachol 017. The mechanism of action of indirect-acting cholinomimetic agents is: a) Binding to and activation of muscarinic or nicotinic receptors b) Inhibition of the hydrolysis of endogenous acetylcholine c) Stimulation of the action of acetylcholinesterase d) Releasing acetylcholine from storage sites 018. Indicate a reversible cholinesterase inhibitor: a) Isoflurophate b) Carbochol c) Physostigmine d) Parathion 019. Which of the following cholinesterase inhibitors is irreversible? a) Physostigmine b) Edrophonium c) Neostigmine d) Isoflurophate 020. Indicate cholinesterase activator: a) Pralidoxime b) Edrophonium c) Pilocarpine d) Isoflurophate 021. Isofluorophate increases all of the following effects except: a) Lacrimation b) Bronchodilation c) Muscle twitching d) Salivation 022. Indicate a cholinesterase inhibitor, which has an additional direct nicotinic agonist effect: a) Edrophonium b) Carbochol c) Neostigmine d) Lobeline 18 023. Сholinesterase inhibitors do not produce: a) Bradycardia, no change or modest fall in blood pressure b) Increased strength of muscle contraction, especially in muscles weakened by myasthenia gravis c) Miosis and reduction of intraocular pressure d) Dramatic hypertension and tachycardia 024. Which of the following cholinomimetics is commonly used in the treatment of glaucoma? a) Pilocarpine b) Lobeline c) Acethylcholine d) Neostigmine 025. Indicate the organophosphate cholinesterase inhibitor, which can be made up in an aqueous solution for ophthalmic use and retains its activity within a week: a) Physoctigmine b) Edrophonium c) Echothiophate d) Neostigmine 026. Which of the following cholinomimetics is most widely used for paralytic ileus and atony of the urinary bladder? a) Lobeline b) Neostigmine c) Pilocarpine d) Echothiophate 027. Chronic long-term therapy of myasthenia is usually accomplished with: a) Edrophonium b) Neostigmine c) Echothiophate d) Carbachol 028. Which of the following cholinomimetics is a drug of choice for reversing the effects of nondepolarizing neuromuscular relaxants? a) Echothiophate b) Physostigmine c) Edrophonium d) Pilocarpine 029. Indicate the reversible cholinesterase inhibitor, which penetrates the blood-brain barrier: a) Physostigmine b) Edrophonium c) Neostigmine d) Piridostigmine 030. Which of the following cholinomimetics is used in the treatment of atropine intoxication? a) Neostigmine b) Carbochol c) Physostigmine d) Lobeline 031. The symptoms of excessive stimulation of muscarinic receptors include all of the following EXCEPT: a) Abdominal cramps, diarrhea b) Increased salivation, excessive bronchial secretion c) Miosis, bradycardia d) Weakness of all skeletal muscles 032. The excessive stimulation of muscarinic receptors by pilocarpine and choline esters is blocked competitively by: a) Edrophonium b) Atropine c) Pralidoxime d) Echothiophate 033. The toxic effects of a large dose of nicotine include all of the following EXCEPT: a) Hypotension and bradycardia b) Convulsions, coma and respiratory arrest c) Skeletal muscle depolarization blockade and respiratory paralysis d) Hypertension and cardiac arrhythmias 034. The dominant initial sights of acute cholinesterase inhibitors intoxication include all of the following except: a) Salivation, sweating b) Mydriasis c) Bronchial constriction 19 d) Vomiting and diarrhea 035. Which of the following drugs is used for acute toxic effects of organophosphate cholinesterase inhibitors? a) Atropine b) Pilocarpine c) Pralidoxime d) Edrophonium PART III Cholinoreceptor blocking drugs 001. The group of nicotinic receptor-blocking drugs consists of: a) Ganglion-blockers b) Atropine-similar drugs c) Neuromuscular junction blockers d) Both a and c 002. M3 receptor subtype is located: a) In the myocardium b) In sympathetic postganglionic neurons c) On effector cell membranes of glandular and smooth muscle cells d) On the motor end plates 003. Which of the following drugs is both a muscarinic and nicotinic blocker? a) Atropine b) Benztropine c) Hexamethonium d) Succinylcholine 004. Indicate a muscarinic receptor-blocking drug: a) Scopolamine b) Pipecuronium c) Trimethaphan d) Pilocarpine 005. Which of the following agents is a ganglion-blocking drug? a) Homatropine b) Hexamethonium c) Rapacuronium d) Edrophonium 006. Indicate the skeletal muscle relaxant, which is a depolarizing agent: a) Vencuronium b) Scopolamine c) Succinylcholine d) Hexamethonium 007. Which of the following drugs is a nondepolarizing muscle relaxant? a) Pancuronium b) Succinylcholine c) Hexamethonium d) Scopolamine 008. Indicate the drug, which is rapidly and fully distributed into CNS and has a greater effect than most other antimuscarinic agents? a) Atropine b) Scopolamine c) Homatropine d) Ipratropium 009. The effect of the drug on parasympathetic function declines rapidly in all organs EXCEPT: a) Eye b) Heart c) Smooth muscle organs d) Glands 010. The mechanism of atropine action is: a) Competitive ganglion blockade b) Competitive muscarinic blockade c) Competitive neuromuscular blockade d) Noncompetitive neuromuscular blockade 011. The tissues most sensitive to atropine are: 20 a) The salivary, bronchial and sweat glands b) The gastric parietal cells c) Smooth muscle and autonomic effectors d) The heart 012. Atropine is highly selective for: a) M1 receptor subtype b) M2 receptor subtype c) M3 receptor subtype d) All of the above 013. Which of the following antimuscarinic drugs is often effective in preventing or reversing vestibular disturbances, especially motion sickness? a) Atropine b) Ipratropium c) Scopolamine d) Homatropine 014. Atropine causes: a) Miosis, a reduction in intraocular pressure and cyclospasm b) Mydriasis, a rise in intraocular pressure and cycloplegia c) Miosis, a rise in intraocular pressure and cycloplegia d) Mydriasis, a rise in intraocular pressure and cyclospasm 015. Patients complain of dry or “sandy” eyes when receiving large doses of: a) Atropine b) Hexamethonium c) Pilocarpine d) Carbachol 016. All of the following parts of the heart are very sensitive to muscarinic receptor blockade except: a) Atria b) Sinoatrial node c) Atrioventricular node d) Ventricle 017. Atropine causes: a) Bradycardia, hypotension and bronchoconstriction b) Tachycardia, little effect on blood pressure and bronchodilation c) Decrease in contractile strength, conduction velocity through the AV node d) Tachycardia, hypertensive crisis and bronchodilation 018. Atropine is frequently used prior to administration of inhalant anesthetics to reduce: a) Muscle tone b) Secretions c) Nausea and vomiting d) All of the above 019. Atropine is now rarely used for the treatment of peptic ulcer because of: a) Slow gastric empting and prolongation of the exposure of the ulcer bed to acid b) Low efficiency and necessity of large doses c) Adverse effects d) All of the above 020. Which of the following antimuscarinic drugs is a selective M1 blocker? a) Atropine b) Scopolamine c) Pirenzepine d) Homatropine 021. Atropine causes: a) Spasmolitic activity b) Intestinal hypermotility c) Stimulation of contraction in the gut d) Stimulation of secretory activity 022. Which of the following drugs is useful in the treatment of uterine spasms? a) Carbachol b) Vecuronium c) Atropine d) Edrophonium 023. Atropine may cause a rise in body temperature (atropine fever): 21 a) In adults b) In pregnant women c) In infants and children d) All of the above 024. The pharmacologic actions of scopolamine most closely resemble those of: a) Hexamethonium b) Atropine c) Succinylcholine d) Pilocarpine 025. Compared with atropine, scopolamine has all of the following properties EXCEPT: a) More marked central effect b) Less potent in decreasing bronchial, salivary and sweat gland secretion c) More potent in producing mydriasis and cycloplegia d) Lower effects on the heart, bronchial muscle and intestines 026. Which of the following drugs is useful in the treatment of Parkinson′s disease? a) Benztropine b) Edrophonium c) Succinylcholine d) Hexamethonium 027. Indicate the antimuscarinic drug, which is used as a mydriatic: a) Pilocarpine b) Neostigmine c) Homatropine d) Ipratropium 028. Which of the following agents is used as an inhalation drug in asthma? a) Atropine b) Ipratropium c) Lobeline d) Homatropine 029. Which of the following agents is most effective in regenerating cholinesterase associated with skeletal muscle neuromuscular junctions? a) Suscinilcholine b) Pralidoxime c) Pirenzepine d) Propiverine 030. Indicate an antimuscarinic drug, which is effective in the treatment of mushroom poising: a) Pralidoxime b) Pilocarpine c) Homatropine d) Atropine 031. Antimuscarinics are used in the treatment of the following disorders EXCEPT: a) Motion sickness b) Glaucoma c) Hyperhidrosis d) Asthma 032. The atropine poisoning includes all of the following symptoms EXCEPT: a) Mydriasis, cycloplegia b) Hyperthermia, dry mouth, hot and flushed skin c) Agitation and delirium d) Bradicardia, orthostatic hypotension 033. The treatment of the antimuscarinic effects can be carried out with: a) Neostigmine b) Hexametonium c) Homatropine d) Acetylcholine 034. Contraindications to the use of antimuscarinic drugs are all of the following except: a) Glaucoma b) Myasthenia c) Bronchial asthma d) Paralytic ileus and atony of the urinary bladder 035. Hexamethonium blocks the action of acethylcholine and similar agonists at: 22 a) Muscarinic receptor site b) Neuromuscular junction c) Autonomic ganglia d) Axonal transmission 036. The applications of the ganglion blockers have disappeared because of all of the following reasons EXCEPT: a) Orthostatic hypotension b) Lack of selectivity c) Homeostatic reflexes block d) Respiratory depression 037. Which of the following agents is a short-acting ganglion blocker? a) Homatropine b) Trimethaphane c) Hexamethonium d) Pancuronium 038. Indicate the ganglion-blocking drug, which can be taken orally for the treatment of hypertension? a) Mecamylamine b) Scopolamine c) Trimethaphane d) Vecocuronium 039. The systemic effects of hexamethonium include all of the following EXCEPT: a) Reduction of both peripheral vascular resistance and venous return b) Partial mydriasis and loss of accommodation c) Constipation and urinary retention d) Stimulation of thermoregulatory sweating 040. Ganglion blocking drugs are used for the following emergencies EXCEPT: a) Hypertensive crises b) Controlled hypotension c) Cardiovascular collapse d) Pulmonary edema 041. Agents that produce neuromuscular blockade act by inhibiting: a) Interaction of acetylcholine with cholinergic receptors b) Release of acetylcholine from prejunctional membrane c) Packaging of acetylcholine into synaptic vesicles d) Reuptake of acetylcholine into the nerve ending 042. Skeletal muscle relaxation and paralysis can occur from interruption of functions at several sites, including all of the following EXCEPT: a) Nicotinic acethylcholine receptors b) Muscarinic acethylcholine receptors c) The motor end plate d) Contractile apparatus 043. Nondepolarisation neuromuscular blocking agents: a) Block acetylcholine reuptake b) Prevent access of the transmitter to its receptor and depolarization c) Block transmission by an excess of a depolarizing agonist d) All of the above 044. Which of the following drugs has “double-acetylcholine” structure? a) Rocuronium b) Carbachol c) Atracurium d) Succylcholine 045. Indicate the long-acting neuromuscular blocking agent: a) Rapacuronium b) Mivacurium c) Tubocurarine d) Rocuronium 046. Which of the following neuromuscular blocking drugs is an intermediate-duration muscle relaxant? a) Vecuronium b) Tubocurarine c) Pancuronium d) Rapacuronium 047. Indicate the nondepolarizing agent, which has the fastest onset of effect? 23 a) Succinylcholine b) Rapacuronium c) Pancuronium d) Tubocurarine 048. Indicate the neuromuscular blocker, whose breakdown product readily crosses the blood-brain barrier and may cause seizures: a) Pancuronium b) Succinylcholine c) Tubocurarine d) Atracurium 049. Which competitive neuromuscular blocking agent could be used in patients with renal failure? a) Atracurium b) Succinylcholine c) Pipecuronium d) Doxacurium 050. Indicate the nondepolarizing agent, which has short duration of action: a) Succinylcholine b) Tubocurarine c) Mivacurium d) Pancuronium 051. Which depolarizing agent has the extremely brief duration of action? a) Mivacurium b) Rapacuronium c) Rocuronium d) Succinylcholine 052. Neuromuscular blockade by both succinylcholine and mivacurium may be prolonged in patients with: a) Renal failure b) An abnormal variant of plasma cholinesterase c) Hepatic disease d) Both b and c 053. Depolarizing agents include all of the following properties EXCEPT: a) Interact with nicotinic receptor to compete with acetylcholine without receptor activation b) React with the nicotinic receptor to open the channel and cause depolarisation of the end plate c) Cause desensitization, noncompetive block manifested by flaccid paralysis d) Cholinesterase inhibitors do not have the ability to reverse the blockade 054. Which of the following neuromuscular blockers causes transient muscle fasciculations? a) Mivacurium b) Pancuronium c) Succinylcholine d) Tubocurarine 055. Indicate muscles, which are more resistant to block and recover more rapidly: a) Hand b) Leg c) Neck d) Diaphragm 056. Which neuromuscular blocking agent has the potential to cause the greatest release of histamine? a) Succylcholine b) Tubocurarine c) Pancuronium d) Rocuronium 057. Which of the following muscular relaxants causes hypotension and bronchospasm? a) Vecuronium b) Succinylcholine c) Tubocurarine d) Rapacuronium 058. Indicate the neuromuscular blocker, which causes tachycardia: a) Tubocurarine b) Atracurium c) Pancuronium d) Succinylcholine 059. Which of the following neuromuscular blocking agents cause cardiac arrhythmias? 24 a) Vecuronium b) Tubocurarine c) Rapacuronium d) Succinylcholine 060. Effects seen only with depolarizing blockade include all of the following EXCEPT: a) Hypercaliemia b) A decrease in intraocular pressure c) Emesis d) Muscle pain 061. Which neuromuscular blocking agent is contraindicated in patients with glaucoma? a) Tubocurarine b) Succinylcholine c) Pancuronium d) Gallamine 062. Indicate the following neuromuscular blocker, which would be contraindicated in patients with renal failure: a) Pipecuronium b) Succinylcholine c) Atracurium d) Rapacuronium 063. All of the following drugs increase the effects of depolarizing neuromuscular blocking agents EXCEPT: a) Aminoglycosides b) Antiarrhythmic drugs c) Nondepolarizing blockers d) Local anesthetics 064. Which of the following diseases can augment the neuromuscular blockade produced by nondepolarizing muscle relaxants? a) Myasthenia gravis b) Burns c) Asthma d) Parkinsonism 065. Indicate the agent, which effectively antagonizes the neuromuscular blockade caused by nondepolarizing drugs: a) Atropine b) Neostigmine c) Acetylcholine d) Pralidoxime PART IV Adrenoreceptor activating drugs 001. Sympathetic stimulation is mediated by: a) Release of norepinephrine from nerve terminals b) Activation of adrenoreceptors on postsynaptic sites c) Release of epinephrine from the adrenal medulla d) All of the above 002. Characteristics of epinephrine include all of the following EXCEPT: a) It is synthesized into the adrenal medulla b) It is synthesized into the nerve ending c) It is transported in the blood to target tissues d) It directly interacts with and activates adrenoreceptors 003. Which of the following sympathomimetics acts indirectly? a) Epinephrine b) Norepinephrine c) Ephedrine d) Methoxamine 004. Indirect action includes all of the following properties EXCEPT: a) Displacement of stored catecholamines from the adrenergic nerve ending b) Inhibition of reuptake of catecholamines already released c) Interaction with adrenoreceptors d) Inhibition of the release of endogenous catecholamines from peripheral adrenergic neurons 005. Catecholamine includes following EXCEPT: a) Ephedrine b) Epinephrine c) Isoprenaline 25 d) Norepinephrine 006. Epinephrine decreases intracellular camp levels by acting on: a) α1 receptor b) α2 receptor c) beta1 receptor d) beta2 receptor 007. Which of the following statements is not correct? a) ALFA receptors increase arterial resistence, whereas beta2 receptor promote smooth muscle relaxation b) The skin and splanchic vessels have predominantly alfa receptors c) Vessels in a skeletal muscle may constrict or dilate depending on whether alfa or beta2 receptors are activated d) Skeletal muscle vessels have predominantly alfa receptors and constrict in the presence of epinephrine and norepinephrine 008. Direct effects on the heart are determined largely by: a) Alfa1 receptor b) Alfa2 receptor c) Beta1 receptor d) Beta2 receptor 009. Which of the following effects is related to direct beta1-adrenoreceptor stimulation? a) Bronchodilation b) Vasodilatation c) Tachycardia d) Bradycardia 010. Distribution of alfa adrenoreceptor subtypes is associated with all of the following tissues except those of: a) Heart b) Blood vessels c) Prostate d) Pupillary dilator muscle 011. Beta adrenoreceptor subtypes is contained in all of the following tissues EXCEPT: a) Bronchial muscles b) Heart c) Pupillary dilator muscle d) Fat cells 012. In which of the following tissues both alfa and beta1 adrenergic stimulation produces the same effect? a) Blood vessels b) Intestine c) Uterus d) Bronchial muscles 013. The effects of sympathomimetics on blood pressure are associated with their effects on: a) The heart b) The peripheral resistance c) The venous return d) All of the above 014. A relatively pure alfa agonist causes all of the following effects EXCEPT: a) Increase peripheral arterial resistance b) Increase venous return c) Has no effect on blood vessels d) Reflex bradycardia 015. A nonselective beta receptor agonist causes all of the following effects EXCEPT: a) Increase cardiac output b) Increase peripheral arterial resistance c) Decrease peripheral arterial resistance d) Decrease the mean pressure 016. Which of the following statement is not correct? a) Αlfa agonists cause miosis b) Αlfa agonists cause mydriasis c) Beta antagonists decrease the production of aqueous humor d) Αlfa agonists increase the outflow of aqueous humor from the eye 017. A bronchial smooth muscle contains: a) Αlfa1 receptor b) Αlfa2 receptor c) Beta 1 receptor 26 d) Beta 2 receptor 018. All of the following agents are beta receptor agonists EXCEPT: a) Epinephrine b) Isoproterenol c) Methoxamine d) Dobutamine 019. Which of the following drugs causes bronchodilation without significant cardiac stimulation? a) Isoprenaline b) Terbutaline c) Xylometazoline d) Methoxamine 020. Αlfa-receptor stimulation includes all of the following effects EXCEPT: a) Relaxation of gastrointestinal smooth muscle b) Contraction of bladder base, uterus and prostate c) Stimulation of insulin secretion d) Stimulation of platelet aggregation 021. Beta1 receptor stimulation includes all of the following effects EXCEPT: a) Increase in contractility b) Bronchodilation c) Tachycardia d) Increase in conduction velocity in the atrioventricular node 022. Beta2 receptor stimulation includes all of the following effects EXCEPT: a) Stimulation of renin secretion b) Fall of potassium concentration in plasma c) Relaxation of bladder, uterus d) Tachycardia 023. Hyperglycemia induced by epinephrine is due to: a) Gluconeogenesis (beta2) b) Inhibition of insulin secretion (alfa) c) Stimulation of glycogenolysis (beta2) d) All of the above 024. Which of the following effects is associated with beta3-receptor stimulation? a) Lipolysis b) Decrease in platelet aggregation c) Bronchodilation d) Tachycardia 025. Which of the following statements is not correct? a) Epinephrine acts on both alfa- and beta-receptors b) Norepinephrine has a predominantly beta action c) Methoxamine has a predominantly alfa action d) Isoprenaline has a predominantly beta action 026. Indicate the drug, which is a direct-acting both alfa- and beta-receptor agonist: a) Norepinephrine b) Methoxamine c) Isoproterenol d) Ephedrine 027. Which of the following agents is an alfa1 alfa2 beta1 beta2 receptor agonist? a) Methoxamine b) Albuterol c) Epinephrine d) Norepinephrine 028. Indicate the direct-acting sympathomimetic, which is an alfa1 alfa2 beta1 receptor agonist: a) Isoproterenol b) Ephedrine c) Dobutamine d) Norepinephrine 029. Which of the following agents is an alfa1-selective agonist? a) Norepinephrine b) Methoxamine c) Ritodrine d) Ephedrine 27 030. Indicate the alfa2-selective agonist: a) Xylometazoline b) Epinephrine c) Dobutamine d) Methoxamine 031. Which of the following agents is a nonselective beta receptor agonist? a) Norepinephrine b) Terbutaline c) Isoproterenol d) Dobutamine 032. Indicate the beta1-selective agonist: a) Isoproterenol b) Dobutamine c) Metaproterenol d) Epinephrine 033. Which of the following sympathomimetics is a beta2-selective agonist? a) Terbutaline b) Xylometazoline c) Isoproterenol d) Dobutamine 034. Indicate the indirect-acting sympathomimetic agent: a) Epinephrine b) Phenylephrine c) Ephedrine d) Isoproterenol 035. Epinephrine produces all of the following effects EXCEPT: a) Positive inotropic and chronotropic actions on the heart (beta1 receptor) b) Increase peripheral resistance (alfa receptor) c) Predominance of alfa effects at low concentration d) Skeletal muscle blood vessel dilatation (beta2 receptor) 036. Epinephrine produces all of the following effects EXCEPT: a) Decrease in oxygen consumption b) Bronchodilation c) Hyperglycemia d) Mydriasis 037. Epinephrine is used in the treatment of all of the following disorders EXCEPT: a) Bronchospasm b) Anaphylactic shock c) Cardiac arrhythmias d) Open-angle glaucoma 038. Compared with epinephrine, norepinephrine produces all of the following effects EXCEPT: a) Similar effects on beta1 receptors in the heart and similar potency at an alfa receptor b) Decrease the mean pressure below normal before returning to the control value c) Significant tissue necrosis if injected subcutaneously d) Increase both diastolic and systolic blood pressure 039. Norepinephrine produces: a) Vasoconstriction b) Vasodilatation c) Bronchodilation d) Decresed potassium concentration in the plasma 040. Which of the following direct-acting drugs is a relatively pure alfa agonist, an effective mydriatic and decongestant and can be used to raise blood pressure? a) Epinephrine b) Norepinephrine c) Phenylephrine d) Ephedrine 041. Characteristics of methoxamine include all of the following EXCEPT: a) It is a direct-acting alfa1-receptor agonist b) It increases heart rate, contractility and cardiac output c) It causes reflex bradycardia d) It increases total peripheral resistance 28 042. Which of the following agents is an alfa2-selective agonist with ability to promote constriction of the nasal mucosa? a) Xylometazoline b) Phenylephrine c) Methoxamine d) Epinephrine 043. Indicate the sympathomimetic, which may cause hypotension, presumably because of a clonidine-like effect: a) Methoxamine b) Phenylephrine c) Xylometazoline d) Isoproterenol 044. Isoproterenol is: a) Both an alfa- and beta-receptor agonist b) beta1-selective agonist c) beta2-selective agonist d) Nonselective beta receptor agonist 045. Isoproterenol produces all of the following effects EXCEPT: a) Increase in cardiac output b) Fall in diastolic and mean arterial pressure c) Bronchoconstriction d) Tachycardia 046. Characteristics of dobutamine include all of the following EXCEPT: a) It is a relatively beta1-selective synthetic catecholamine b) It is used to treat bronchospasm c) It increases atrioventricular conduction d) It causes minimal changes in heart rate and systolic pressure 047. Characteristics of salmeterol include all of the following EXCEPT: a) It is a potent selective beta2 agonist b) It causes uterine relaxation c) It stimulates heart rate, contractility and cardiac output d) It is used in the therapy of asthma 048. Characteristics of ephedrine include all of the following EXCEPT: a) It acts primarily through the release of stored cathecholamines b) It is a mild CNS stimulant c) It causes tachyphylaxis with repeated administration d) It decreases arterial pressure 049. Ephedrine causes: a) Miosis b) Bronchodilation c) Hypotension d) Bradycardia 050. Compared with epinephrine, ephedrine produces all of the following features EXCEPT: a) It is a direct-acting sympathomimetic b) It has oral activity c) It is resistant to MAO and has much longer duration of action d) Its effects are similar, but it is less potent 051. Which of the following sympathomimetics is preferable for the treatment of chronic orthostatic hypotension? a) Epinephrine b) Norepinephrine c) Ephedrine d) Salmeterol 052. Indicate the sympathomimetic drug, which is used in a hypotensive emergency: a) Xylometazoline b) Ephedrine c) Terbutaline d) Phenylephrine 053. Which of the following sympathomimetics is preferable for the emergency therapy of cardiogenic shock? a) Epinephrine b) Dobutamine c) Isoproterenol d) Methoxamine 29 054. Indicate the sympathomimetic agent, which is combined with a local anesthetic to prolong the duration of infiltration nerve block: a) Epinephrine b) Xylometazoline c) Isoproterenol d) Dobutamine 055. Which of the following sympathomimetics is related to short-acting topical decongestant agents? a) Xylometazoline b) Terbutaline c) Phenylephrine d) Norepinephrine 056. Indicate the long-acting topical decongestant agents: a) Epinephrine b) Norepinephrine c) Phenylephrine d) Xylometazoline 057. Which of the following topical decongestant agents is an alfa2-selective agonist? a) Phenylephrine b) Xylometazoline c) Ephedrine d) Epinephrine 058. Indicate the sympathomimetic, which may be useful in the emergency management of cardiac arrest: a) Methoxamine b) Phenylephrine c) Epinephrine d) Xylometazoline 059. Which of the following sympathomimetics is used in the therapy of bronchial asthma? a) Formoterol b) Norepinephrine c) Methoxamine d) Dobutamine 060. Indicate the agent of choice in the emergency therapy of anaphylactic shock: a) Methoxamine b) Terbutaline c) Norepinephrine d) Epinephrine 061. Which of the following sympathomimetics is an effective mydriatic? a) Salmeterol b) Phenylephrine c) Dobutamine d) Norepinephrine 062. The adverse effects of sympathomimetics include all of the following EXCEPT: a) Drug-induced parkinsonism b) Cerebral hemorrhage or pulmonary edema c) Myocardial infarction d) Ventricular arrhythmias PART V Adrenoreceptor antagonist drugs 001. Which of the following drugs is a nonselective alfa receptor antagonist? a) Prazosin b) Phentolamine c) Metoprolol d) Reserpine 002. Indicate the alfa1-selective antagonist: a) Phentolamine b) Dihydroergotamine c) Prazosin d) Labetalol 003. Which of the following agents is an alfa2–selective antagonist? a) Yohimbine b) Tamsulosin 30 c) Tolazoline d) Prazosin 004. Indicate the irreversible alfa receptor antagonist: a) Tolazoline b) Labetalol c) Prazosin d) Phenoxybenzamine 005. Which of the following drugs is an nonselective beta receptor antagonist? a) Metoprolol b) Atenolol c) Propranolol d) Acebutolol 006. Indicate the beta1-selective antagonist: a) Propranolol b) Metoprolol c) Carvedilol d) Sotalol 007. Which of the following agents is a beta2–selective antagonist? a) Tolazolin b) Pindolol c) Ergotamin d) Butoxamine 008. Indicate the beta adrenoreceptor antagonist, which has partial beta–agonist activity: a) Propranolol b) Metoprolol c) Pindolol d) Betaxolol 009. Which of the following drugs is a reversible nonselective alfa, beta antagonist? a) Labetalol b) Phentolamine c) Metoprolol d) Propranolol 010. Indicate the indirect-acting adrenoreceptor blocking drug: a) Tolazoline b) Reserpine c) Carvedilol d) Prazosin 011. The principal mechanism of action of adrenoreceptor antagonists is: a) Reversible or irreversible interaction with adrenoreceptors b) Depletion of the storage of catecholamines c) Blockade of the amine reuptake pumps d) Nonselective MAO inhibition 012. Characteristics of alfa-receptor antagonists include all of the following EXCEPT: a) They cause a fall in peripheral resistance and blood pressure b) They cause epinephrine reversal (convert a pressor response to a depressor response) c) Bronchospasm d) They may cause postural hypotension and reflex tachycardia 013. Which of the following drugs is an imidazoline derivative and a potent competitive antagonist at both alfa1 and alfa2 receptors? a) Prazosin b) Labetalol c) Phenoxybenzamine d) Phentolamine 014. Characteristics of phentolamine include all of the following EXCEPT: a) Reduction in peripheral resistance b) Stimulation of responses to serotonin c) Tachycardia d) Stimulation of muscarinic, H1 and H2 histamine receptors 015. The principal mechanism of phentolamine-induced tachycardia is: a) Antagonism of presynaptic alfa2 receptors enhances norepinephrine release, which causes cardiac stimulation via unblocked beta receptors 31 b) Baroreflex mechanism c) Direct effect on the heart by stimulation of beta1 receptors d) Inhibition of transmitter reuptake at noradrenergic synapses 016. Nonselective alfa-receptor antagonists are most useful in the treatment of: a) Asthma b) Cardiac arrhythmias c) Pheochromocytoma d) Chronic hypertension 017. The main reason for using alfa-receptor antagonists in the management of pheochromocytoma is: a) Inhibition of the release of epinephrine from the adrenal medulla b) Blockade of alfa2 receptors on vascular smooth muscle results in epinephrine stimulation of unblocked alfa2 receptors c) Direct interaction with and inhibition of beta2 adrenoreceptors d) Antagonism to the release of renin 018. Which of the following drugs is useful in the treatment of pheochromocytoma? a) Phenylephrine b) Propranolol c) Phentolamine d) Epinephrine 019. Indicate adrenoreceptor antagonist agents, which are used for the management of pheochromocytoma: a) Selective beta2-receptor antagonists b) Nonselective beta-receptor antagonists c) Indirect-acting adrenoreceptor antagonist drugs d) Αlfa-receptor antagonists 020. The principal adverse effects of phentolamine include all of the following EXCEPT: a) Diarrhea b) Bradycardia c) Arrhythmias d) Myocardial ischemia 021. Indicate the reversible nonselective alfa-receptor antagonist, which is an ergot derivative: a) Ergotamine b) Prazosin c) Phenoxybenzamine d) Carvedilol 022. Indicate an alfa-receptor antagonist, which binds covalently to alfa receptors, causing irreversible blockade of long duration (14-48 hours or longer): a) Phentolamine b) Phenoxybenzamine c) Ergotamine d) Prazosin 023. Compared with phentolamine, prazosin has all of the following features EXCEPT: a) Irreversible blockade of alfa receptors b) Highly selective for alfa1 receptors c) The relative absence of tachycardia d) Persistent block of alfa1 receptors 024. Which of the following statements is not correct? a) There are at least three subtypes of alfa1 receptors, designated alfa1a, alfa1b and alfa1d b) ALFA1a subtype mediates prostate smooth muscle contraction c) ALFA1b subtype mediates vascular smooth muscle contraction d) ALFA1a subtype mediates both vascular and prostate smooth muscle contraction 025. Indicate an alfa1 adrenoreceptor antagonist, which has great selectivity for alfa1a subtype: a) Prazosin b) Tamsulosin c) Phenoxybenzamine d) Phentolamine 026. Subtype-selective alfa1 receptor antagonists such as tamsulosin, terazosin, alfusosin are efficacious in: a) Hyperthyroidism b) Cardiac arrhythmias c) Benign prostatic hyperplasia (BPH) d) Asthma 32 027. Indicate an alfa receptor antagonist, which is an efficacious drug in the treatment of mild to moderate systemic hypertension: a) Phentolamine b) Tolazoline c) Ergotamine d) Prazosin 028. Which of the following alfa receptor antagonists is useful in reversing the intense local vasoconstriction caused by inadvertent infiltration of norepinephrine into subcutaneous tissue during intravenous administration? a) Propranolol b) Phentolamine c) Tamsulosin d) Ergotamine 029. Beta-blocking drugs-induced chronically lower blood pressure may be associated with theirs effects on: a) The heart b) The blood vessels c) The renin-angiotensin system d) All of the above 030. Characteristics of beta-blocking agents include all of the following EXCEPT: a) They occupy beta receptors and competitively reduce receptor occupancy by catecholamines or other beta agonists b) They do not cause hypotension in individuals with normal blood pressure c) They induce depression and depleted stores of catecholamines d) They can cause blockade in the atrioventricular node 031. Beta-receptor antagonists have all of the following cardiovascular effects EXCEPT: a) The negative inotropic and chronotropic effects b) Acute effects of these drugs include a fall in peripheral resistance c) Vasoconstriction d) Reduction of the release of renin 032. Beta-blocking agents have all of the following effects except: a) Increase plasma concentrations of HDL and decrease of VLDL b) Bronchoconstriction c) Decrease of aqueous humor prodaction d) “membrane-stabilizing” action 033. Beta-receptor antagonists cause: a) Stimulation of lipolysis b) Stimulation of gluconeogenesis c) Inhibition of glycogenolysis d) Stimulation of insulin secretion 034. Propranolol has all of the following cardiovascular effects EXCEPT: a) It decreases cardiac work and oxygen demand b) It reduces blood flow to the brain c) It inhibits the renin secretion d) It increases the atrioventricular nodal refractory period 035. Propranolol-induced adverse effects include all of the following EXCEPT: a) Bronchoconstriction b) “supersensitivity” of beta-adrenergic receptors (rapid withdrawal) c) Hyperglycemia d) Sedation, sleep disturbances, depression and sexual dysfunction 036. Propranolol is used in the treatment all of the following diseases EXCEPT: a) Cardiovascular diseases b) Hyperthyroidism c) Migraine headache d) Bronchial asthma 037. Metoprolol and atenolol: a) Are members of the beta1-selective group b) Are nonselective beta antagonists c) Have intrinsic sympathomimetic activity d) Have an anesthetic action 038. Which of the following beta receptor antagonists is preferable in patients with asthma, diabetes or peripheral vascular diseases? a) Propranolol b) Metoprolol 33 c) Nadolol d) Timolol 039. Indicate a beta receptor antagonist, which has very long duration of action: a) Metoprolol b) Propranolol c) Nadolol d) Pindolol 040. Indicate a beta1-selective receptor antagonist, which has very long duration of action: a) Betaxolol b) Sotalol c) Nadolol d) Metoprolol 041. Which of the following drugs is a nonselective beta-blocker without intrinsic sympathomimetic or local anesthetic activity and used for the treatment of life-threatening ventricular arrhythmias? a) Propranolol b) Oxprenolol c) Sotalol d) Atenolol 042. Indicate a beta receptor antagonist with intrinsic sympathomimetic activity: a) Propranolol b) Oxprenolol c) Metoprolol d) Carvedilol 043. Pindolol, oxprenolol have all of the following properties EXCEPT: a) They are nonselective beta antagonists b) They have no partial agonist activity c) They are less likely to cause bradycardia and abnormalities in plasma lipids d) They are effective in hypertension and angina 044. Which of the following drugs has both alfa1-selective and beta-blocking effects? a) Labetalol b) Betaxolol c) Propranolol d) Timolol 045. Characteristics of carvedilol include all of the following EXCEPT: a) It is a beta1-selective antagonist b) It has both alfa1-selective and beta-blocking effects c) It attenuates oxygen free radical-initiated lipid peroxidation d) It inhibits vascular smooth muscle mitogenesis 046. Indicate the adrenoreceptor antagonist drug, which is a rauwolfia alkaloid: a) Prazosin b) Propranolol c) Reserpine d) Phentolamine 047. Characteristics of reserpine include all of the following EXCEPT: a) It inhibits the uptake of norepinephrine into vesicles and MAO b) It decreases cardiac output, peripheral resistance and inhibits pressor reflexes c) It may cause a transient sympathomimetic effect d) It depletes stores of catecholamines and serotonin in the brain 048. Indicate a beta-blocker, which is particularly efficacious in thyroid storm: a) Pindolol b) Sotalol c) Phentolamine d) Propranolol 049. Beta-receptor blocking drugs are used in the treatment all of the following diseases EXCEPT: a) Hypertension, ischemic heart disease, cardiac arrhythmias b) Glaucoma c) Pheochromocytoma d) Hyperthyroidism 050. Beta-blocker-induced adverse effects include all of the following EXCEPT: a) Bronchoconstriction b) Depression of myocardial contractility and excitability 34 c) “supersensitivity” of beta-receptors associated with rapid withdrawal of drugs d) Hyperglycemia (3) AGENTS, CONTROLLING THE FUNCTIONS OF THE CENTRAL NERVOUS SYSTEM PART I Hypnotic drugs 001. Hypnotic drugs are used to treat: a) Psychosis b) Sleep disorders c) Narcolepsy d) Parkinsonian disorders 002. Hypnotic drugs should: a) Reduce anxiety and exert a calming effect b) Induce absence of sensation c) Produce drowsiness, encourage the onset and maintenance of sleep d) Prevent mood swings in patients with bipolar affective disorders 003. Which of the following chemical agents are used in the treatment of insomnia? a) Benzodiazepines b) Imidazopyridines c) Barbiturates d) All of the above 004. Select a hypnotic drug, which is a benzodiazepine derivative: a) Zolpidem b) Flurazepam c) Secobarbital d) Phenobarbitone 005. Tick a hypnotic agent – a barbituric acid derivative: a) Flurazepam b) Zaleplon c) Thyopental d) Triazolam 006. Select a hypnotic drug, which is an imidazopyridine derivative: a) Pentobarbital b) Temazepam c) Zolpidem d) Chloral hydrate 007. Which of the following hypnotic agents is absorbed slowly? a) Phenobarbital b) Flurazepam c) Triazolam d) Temazepam 008. Which of the following barbiturates is an ultra-short-acting drug? a) Secobarbital b) Amobarbital c) Thiopental d) Phenobarbital 009. Indicate the barbituric acid derivative, which has 4-5 days elimination half-life: a) Secobarbital b) Thiopental c) Phenobarbital d) Amobarbital 010. Indicate the hypnotic benzodiazepine, which has the shortest elimination half-life: a) Temazepam b) Triazolam c) Flurazepam d) Diazepam 011. Which of the following hypnotic drugs is more likely to cause cumulative and residual effects? a) Zolpidem b) Temazepam c) Phenobarbital d) Triazolam 35 012. Which of the following hypnotic drugs increases the activity of hepatic drug-metabolizing enzyme systems? a) Phenobarbital b) Zolpidem c) Flurazepam d) Zaleplon 013. Hepatic microsomal drug-metabolizing enzyme induction leads to: a) Barbiturate tolerance b) Cumulative effects c) Development of physical dependence d) “hangover” effects 014. Hypnotic benzodiazepines are more powerful enzyme inducers than barbiturates. a) True b) False 015. Indicate the hypnotic drug, which does not change hepatic drug-metabolizing enzyme activity? a) Flurazepam b) Zaleplon c) Triazolam d) All of the above 016. Barbiturates increase the rate of metabolism of: a) Anticoagulants b) Digitalis compounds c) Glucocorticoids d) All of the above 017. Which of the following agents inhibits hepatic metabolism of hypnotics? a) Flumasenil b) Cimetidin c) Phenytoin d) Theophylline 018. Which of the following factors can influence the biodisposition of hypnotic agents? a) Alterations in the hepatic function resulting from a disease b) Old age c) Drug-induced increases or decreases in microsomal enzyme activities d) All of the above 019. Which of the following hypnotics is preferred for elderly patients? a) Phenobarbital b) Flurozepam c) Temazepam d) Secobarbital 020. Which of the following hypnotics is preferred in patients with limited hepatic function? a) Zolpidem b) Amobarbital c) Flurozepam d) Pentobarbital 021. Indicate the mechanism of barbiturate action (at hypnotic doses): a) Increasing the duration of the GABA-gated Cl- channel openings b) Directly activating the chloride channels c) Increasing the frequency of Cl- channel opening events d) All of the above 022. Imidazopyridines are: a) Partial agonists at brain 5-TH1A receptors b) Selective agonists of the BZ1 (omega1) subtype of BZ receptors c) Competitive antagonists of BZ receptors d) Nonselective agonists of both BZ1 and BZ2 receptor subtypes 023. Which of the following hypnotic agents is a positive allosteric modulator of GABAA receptor function? a) Zaleplon b) Flurazepam c) Zolpidem d) All of the above 024. Indicate a hypnotic drug - a selective agonist at the BZ1 receptor subtype: a) Flurazepam b) Zolpidem 36 c) Triazolam d) Flumazenil 025. Which of the following hypnotic agents is able to interact with both BZ1 and BZ2 receptor subtypes? a) Zaleplon b) Phenobarbital c) Flurazepam d) Zolpidem 026. Indicate the competitive antagonist of BZ receptors: a) Flumazenil b) Picrotoxin c) Zolpidem d) Temazepam 027. Flumazenil blocks the actions of: a) Phenobarbital b) Morphine c) Zolpidem d) Ethanol 028. Indicate the agent, which interferes with GABA binding: a) Flurazepam b) Bicuculline c) Thiopental d) Zolpidem 029. Which of the following agents blocks the chloride channel directly? a) Secobarbital b) Flumazenil c) Zaleplon d) Picrotoxin 030. Which of the following agents is preferred in the treatment of insomnia? a) Barbiturates b) Hypnotic benzodiazepines c) Ethanol d) Phenothiazide 031. Barbiturates are being replaced by hypnotic benzodiazepines because of: a) Low therapeutic index b) Suppression in REM sleep c) High potential of physical dependence and abuse d) All of the above 032. Which of the following benzodiazepines is used mainly for hypnosis? a) Clonozepam b) Lorazepam c) Flurazepam d) Midazolam 033. Indicate the main claim for an ideal hypnotic agent: a) Rapid onset and sufficient duration of action b) Minor effects on sleep patterns c) Minimal “hangover” effects d) All of the above 034. Which stage of sleep is responsible for the incidence of dreams? a) REM sleep b) Slow wave sleep c) Stage 2NREM sleep d) All of the above 035. During slow wave sleep (stage 3 and 4 NREM sleep): a) Dreams occur b) The secretion of adrenal steroids is at its highest c) Somnambulism and nightmares occur d) The secretion of somatotropin is at its lowest 036. All of the hypnotic drugs induce: a) Increase the duration of REM sleep b) Decrease the duration of REM sleep c) Do not alter the duration of REM sleep 37 d) Increase the duration of slow wave sleep 037. Which of the following hypnotic drugs causes least suppression of REM sleep? a) Flumazenil b) Phenobarbital c) Flurazepam d) Secobarbital 038. Although the benzodiazepines continue to be the agents of choice for insomnia, they have: a) The possibility of psychological and physiological dependence b) Synergistic depression of CNS with other drugs (especially alcohol) c) Residual drowsiness and daytime sedation d) All of the above 039. Hypnotic benzodiazepines can cause: a) A dose-dependent increase in both REM and slow wave sleep b) Do not change sleep patterns c) A dose-dependent decrease in both REM and slow wave sleep d) A dose-dependent increase in REM sleep and decrease in slow wave sleep 040. Which one of the following hypnotic benzodiazepines is more likely to cause rebound insomnia? a) Triazolam b) Flurazepam c) Temazepam d) All of the above 041. Which of the following hypnotic benzodiazepines is more likely to cause “hangover” effects such as drowsiness, dysphoria, and mental or motor depression the following day? a) Temazepam b) Triazolam c) Flurazepam d) None of the above 042. Indicate the hypnotic drug, which binds selectively to the BZ1 receptor subtype, facilitating GABAergic inhibition: a) Thiopental b) Zolpidem c) Flurazepam d) Phenobarbital 043. Which of the following statements is correct for zolpidem? a) Causes minor effects on sleep patterns b) The risk of development of tolerance and dependence is less than with the use of hypnotic benzodiazepines c) Has minimal muscle relaxing and anticonvulsant effects d) All of the above 044. Which agent exerts hypnotic activity with minimal muscle relaxing and anticonvulsant effects? a) Flurazepam b) Triazolam c) Zaleplon d) None of the above 045. Zolpidem and zaleplon have effectiveness similar to that of hypnotic benzodiazepines in the management of sleep disorders. a) True b) False 046. Which of the following hypnotic drugs is used intravenously as anesthesia? a) Thiopental b) Phenobarbital c) Flurazepam d) Zolpidem 047. Indicate the usual cause of death due to overdose of hypnotics: a) Depression of the medullar respiratory center b) Hypothermia c) Cerebral edema d) Status epilepticus 048. Toxic doses of hypnotics may cause a circulatory collapse as a result of: a) Blocking alfa adrenergic receptors b) Increasing vagal tone c) Action on the medullar vasomotor center d) All of the above 38 PART II Antiseizure drugs 001. The mechanism of action of antiseizure drugs is: a) Enhancement of GABAergic (inhibitory) transmission b) Diminution of excitatory (usually glutamatergic) transmission c) Modification of ionic conductance d) All of the above mechanisms 002. Which of the following antiseizure drugs produces enhancement of GABA-mediated inhibition? a) Ethosuximide b) Carbamazepine c) Phenobarbital d) Lamotrigine 003. Indicate an antiseizure drug, which has an impotent effect on the T-type calcium channels in thalamic neurons? a) Carbamazepin b) Lamotrigine c) Ethosuximide d) Phenytoin 004. Which of the following antiseizure drugs produces a voltage-dependent inactivation of sodium channels? a) Lamotrigine b) Carbamazepin c) Phenytoin d) All of the above 005. Indicate an antiseizure drug, inhibiting central effects of excitatory amino acids: a) Ethosuximide b) Lamotrigine c) Diazepam d) Tiagabine 006. The drug for partial and generalized tonic-clonic seizures is: a) Carbamazepine b) Valproate c) Phenytoin d) All of the above 007. Indicate an anti-absence drug: a) Valproate b) Phenobarbital c) Carbamazepin d) Phenytoin 008. The drug against myoclonic seizures is: a) Primidone b) Carbamazepine c) Clonazepam d) Phenytoin 009. The most effective drug for stopping generalized tonic-clonic status epilepticus in adults is: a) Lamotrigine b) Ethosuximide c) Diazepam d) Zonisamide 010. Select the appropriate consideration for phenytoin: a) It blocks sodium channels b) It binds to an allosteric regulatory site on the GABA-BZ receptor and prolongs the openings of the Cl-channels c) It effects on Ca2+ currents, reducing the low-threshold (T-type) current d) It inhibits GABA-transaminase, which catalyzes the breakdown of GABA 011. Phenytoin is used in the treatment of: a) Petit mal epilepsy b) Grand mal epilepsy c) Myoclonic seizures d) All of the above 012. Dose-related adverse effect caused by phenytoin is: a) Physical and psychological dependence b) Exacerbated grand mal epilepsy c) Gingival hyperplasia d) Extrapyramidal symptoms 39 013. Granulocytopenia, gastrointestinal irritation, gingival hyperplasia, and facial hirsutism are possible adverse effects of: a) Phenobarbital b) Carbamazepin c) Valproate d) Phenytoin 014. The antiseizure drug, which induces hepatic microsomal enzymes, is: a) Lamotrigine b) Phenytoin c) Valproate d) None of the above 015. The drug of choice for partial seizures is: a) Carbamazepin b) Ethosuximide c) Diazepam d) Lamotrigine 016. The mechanism of action of carbamazepine appears to be similar to that of: a) Benzodiazepines b) Valproate c) P

Pharmacology MCQ PDF - Volga State Medical University 2006

Document Details

Tags

Related

Summary

Full Transcript

Upgrade to continue